Phosphorylation of ERK1/2 and Prognosis of Clear Cell Renal Cell Carcinoma

Urology

Volumn 73, Issue 2, 2009, Pages 394-399

  Lee, Hyun Ju ^a   Kim, Dong Il ^a   Kang, Gyeong Hoon ^a   Kwak, Cheol ^a   Ku, Ja Hyeon ^a   Moon, Kyung Chul ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLEAR CELL CARCINOMA; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; LARGE CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SMALL CELL CARCINOMA; STAINING; TISSUE MICROARRAY; TUMOR CELL; TUMOR VOLUME;

CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 58649090898     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.08.472     Document Type: Article

References (22)

1. McLaughlin J.K., Lipworth L., and Tarone R.E. Epidemiologic aspects of renal cell carcinoma. Semin Oncol 33 (2006) 527-533
2. Lopez-Beltran A., Scarpelli M., Montironi R., et al. 2004 WHO classification of the renal tumors of the adults. Eur Urol 49 (2006) 798-805
3. Shuch B.M., Lam J.S., Belldegrun A.S., et al. Prognostic factors in renal cell carcinoma. Semin Oncol 33 (2006) 563-575
4. Pearson G., Robinson F., Beers Gibson T., et al. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 22 (2001) 153-183
5. Kolch W. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351 (2000) 289-305
6. Hoshino R., Chatani Y., Yamori T., et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18 (1999) 813-822
7. Oka H., Chatani Y., Hoshino R., et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55 (1995) 4182-4187
8. Sobin L.H., and Wittekind C.H. UICC: TNM Classification of Malignant Tumors. 6th ed. (2002), Wiley-Liss, New York
9. Fuhrman S.A., Lasky L.C., and Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6 (1982) 655-663
10. Torii S., Yamamoto T., Tsuchiya Y., et al. ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci 97 (2006) 697-702
11. Handra-Luca A., Bilal H., Bertrand J.C., et al. Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: Association to aggressive tumor behavior and tumor cell proliferation. Am J Pathol 163 (2003) 957-967
12. Vicent S., Lopez-Picazo J.M., Toledo G., et al. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer 90 (2004) 1047-1052
13. Schmitz K.J., Wohlschlaeger J., Alakus H., et al. Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. Virchows Arch 450 (2007) 151-159
14. Chadha K.S., Khoury T., Yu J., et al. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol 13 (2006) 933-939
15. Milde-Langosch K., Bamberger A.M., Rieck G., et al. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 92 (2005) 2206-2215
16. Blackhall F.H., Pintilie M., Michael M., et al. Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res 9 (2003) 2241-2247
17. Sewing A., Wiseman B., Lloyd A.C., et al. High-intensity ref signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 17 (1997) 5588-5597
18. Weiss R.H., Borowsky A.D., Seligson D., et al. p21 is a prognostic marker for renal cell carcinoma: Implications for novel therapeutic approaches. J Urol 177 (2007) 63-68
19. Amato R.J. Renal cell carcinoma: Review of novel single-agent therapeutics and combination regimens. Ann Oncol 16 (2005) 7-15
20. Walter M.S. Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 104 (2005) 2323-2333
21. Gollob J.A., Wilhelm S., Carter C., et al. Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 33 (2006) 392-406
22. Murphy D.A., Makonnen S., Lassoued W., et al. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY 43-9006). Am J Pathol 169 (2006) 1875-1885